Shefali Agarwal


Dr. Shefali Agarwal is Epizyme’s Chief Medical Officer where she led the approval of Tazverik for Relapsed/Refractory Follicular Lymphoma and Epithelioid Sarcoma. She is currently also serving as a Board of Director for FATE Therapeutics. Prior to joining the Epizyme, Shefali held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Shefali also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA® (niraparib) in ovarian cancer. Shefali has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer.

In addition to receiving her medical degree, Shefali holds a Master of Public Health and a Master of Science in Business.